Johnson & Johnson reported first-quarter earnings that surpassed analysts\’ expectations, and the company raised its full-year sales outlook. Despite these positive developments, the stock price declined slightly. This reaction may reflect investor concerns about potential headwinds, such as tariffs or other macroeconomic factors. The company remains a key player in the healthcare sector, with robust financial performance and a strong market position. Please note that this information is intended for informational purposes only and should not be interpreted as investment advice.
— new from Barron\’s